Drugs / APR-2020
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07476183 | Apr 2026 → Apr 2027 expected | Diamond-Blackfan anemia 19 | Apriligen, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APR-2020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07476183 ↗ |
| Route | Other | “After APR-2020 infusion, transduced CD34+ HSPCs are expected to engraft in the BM” NCT07476183 ↗ |